NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for cell based assays. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF's technology before introducing the WOLF to early adopters. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts. We are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures (Highlander Fund and Triton Fund) and other private investors.